EP2411369A1 — Fluoroquinolone carboxylic acid molecular crystals
Assigned to Bausch and Lomb Inc · Expires 2012-02-01 · 14y expired
What this patent protects
A molecular crystal form of (R)-(+)-7-(3-amino-2,3,4,5,6,7-hexahydro-lH- azepin-l-yl)-l,4-dihydro-4-oxoquinoline-3-carboxylic acid is characterized by at least one of: (a) an X-ray powder diffraction ("XRPD") spectrum that comprises peaks at 2Θ angles of 10.6, 15, 19.…
USPTO Abstract
A molecular crystal form of (R)-(+)-7-(3-amino-2,3,4,5,6,7-hexahydro-lH- azepin-l-yl)-l,4-dihydro-4-oxoquinoline-3-carboxylic acid is characterized by at least one of: (a) an X-ray powder diffraction ("XRPD") spectrum that comprises peaks at 2Θ angles of 10.6, 15, 19.7, 21.1, and 22 ° ±0.2 °; (b) a DSC melting peak at 288 °C; (c) a 13 C NMR spectrum having peaks at 23.3, 27.7, 41.1, 54.5, 116.6, and 153.5 ppm; and (d) pKa values of 5.65 and 9.91.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.